Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Septerna, Inc. Common Stock(SEPN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SEPN
10/02/2026: SEPN (5-star) is currently NOT-A-BUY. Pass it for now.
Septerna, Inc. is an early-stage biotechnology company that aims to transform how drugs are developed by targeting GPCRs through its proprietary Native Complex platform. The company's primary strength lies in this innovative technology and its potential to unlock high-value, previously 'undruggable' therapeutic targets. A significant growth opportunity exists with its lead candidate, SEP-786, which is intended to address large metabolic disease markets. Investors face substantial risks including the binary nature of clinical trials, potential for funding dilution, and intense competition from established pharmaceutical giants. This stock is best suited for growth-oriented investors with high risk tolerance who are monitoring progress on key clinical milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Investors seeking exposure to early-stage, high-potential biotech innovation may find the platform technology compelling. |
| Momentum investor | Mixed fit | Momentum will be highly dependent on clinical trial result announcements rather than consistent technical price trends. |
| Value investor | Weak fit | The company lacks current earnings or traditional value metrics, making it unsuitable for standard value strategies. |
| Dividend investor | Weak fit | The company is in a capital-intensive growth phase and does not pay dividends. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks inherently carry high volatility and binary risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price swings based on trial results and regulatory news. |
| Valuation risk | Medium / high | Valuations are based on long-term clinical potential, which is highly subjective and speculative. |
| Competition risk (metabolic drug market) | High | The company competes against well-funded incumbents with massive market share and established distribution. |
| Business quality | Medium | The platform technology is innovative, but the business model remains unproven in the commercial market. |
| Dividend income | Low / none | Capital is strictly reserved for R&D to fuel growth, precluding any dividend payments. |
| Execution risk | High | Success depends entirely on the company's ability to successfully navigate complex clinical trials and regulatory pathways. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 98.23% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.78B USD | Price to earnings Ratio - | 1Y Target Price 54.22 |
Price to earnings Ratio - | 1Y Target Price 54.22 | ||
Volume (30-day avg) 344.2K shares | Beta - | 52 Weeks Range 17.55 - 51.10 | Updated Date 10/02/2026 |
52 Weeks Range 17.55 - 51.10 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Advancing small molecule therapeutics targeting GPCRs through pre-clinical and clinical stages. | The company is currently spending money to invent medicines and has no sales yet, meaning value is tied to the potential success of future drugs. |
Valuation
Trailing PE - | Forward PE 107.53 | Enterprise Value 1.44B | Price to Sales(TTM) 17.96 |
Enterprise Value 1.44B | Price to Sales(TTM) 17.96 | ||
Enterprise Value to Revenue 14.61 | Enterprise Value to EBITDA - | Shares Outstanding 46.68M | Shares Floating 26.41M |
Shares Outstanding 46.68M | Shares Floating 26.41M | ||
Percent Insiders 2.94 | Percent Institutions 99.03 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Septerna, Inc. Common Stock
Exchange NASDAQ | Headquarters South San Francisco, CA, United States | ||
IPO Launch date 2024-10-25 | Co-Founder, CEO & Director Dr. Jeffrey T. Finer M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://septerna.com |
Full time employees 123 | Website https://septerna.com | ||
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.